Status:

COMPLETED

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Lead Sponsor:

AbbVie

Conditions:

Plaque Psoriasis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptima...

Eligibility Criteria

Inclusion

  • Diagnosed with moderate to severe chronic plaque psoriasis for at least 6 months before Baseline (Week 0).
  • Participant must have been on labeled secukinumab or ixekizumab treatment for at least 6 months and are experiencing suboptimal response at time of Screening and Baseline visits.
  • Participant must have a Body Surface Area (BSA) 3%- \<10% and Static Physician Global Assessment (sPGA) 2/3
  • Participant must be eligible for continued biologic therapy as assessed by the investigator.

Exclusion

  • History of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis, psoriatic arthritis.
  • Participant with active skin disease other than plaque psoriasis that could interfere with the assessment of plaque psoriasis.
  • History of any documented active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
  • History of major surgery within 12 weeks prior to Baseline or planned to be performed during the conduct of the trial as assessed by the investigator.
  • Participant with exposure to risankizumab or any IL-23 inhibitors.

Key Trial Info

Start Date :

November 12 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 7 2022

Estimated Enrollment :

244 Patients enrolled

Trial Details

Trial ID

NCT04102007

Start Date

November 12 2019

End Date

November 7 2022

Last Update

November 27 2023

Active Locations (57)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (57 locations)

1

Alliance Dermatology and MOHs /ID# 216001

Phoenix, Arizona, United States, 85032

2

Burke Pharmaceutical Research /ID# 225023

Hot Springs, Arkansas, United States, 71913-6404

3

Arkansas Research Trials /ID# 225497

North Little Rock, Arkansas, United States, 72117

4

Bakersfield Derma & Skin Cance /ID# 213480

Bakersfield, California, United States, 93309